• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PER
Click for more information
2.22% 9.2¢

PERCHERON THERAPEUTICS LIMITED

Market Cap $82.94M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a... Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PER
per-chart
13 14 15
08:46 861 210K
08:46 Last post  nottawombat Comments Created with Sketch.  861  Views Created with Sketch.  210K 
PER
Will PER follow DXB on a similar journey ? 		15/06/24 25 5.2K
15/06/24 Last post  apass Comments Created with Sketch.  25  Views Created with Sketch.  5.2K 
PER
Clean insights and information easily found
2 3
15/06/24 128 27K
15/06/24 Last post  Bluesaint Comments Created with Sketch.  128  Views Created with Sketch.  27K 
PER
Pfizer’s Duchenne muscular dystrophy gene therapy FAILS Ph3 		14/06/24 5 1.3K
14/06/24 Last post  itsagas Comments Created with Sketch.  5  Views Created with Sketch.  1.3K 
PER
Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
2 3
09/06/24 127 31K
09/06/24 Last post  Brett ebony Comments Created with Sketch.  127  Views Created with Sketch.  31K 
PER
Ann: Phase IIb study of ATL1102 in DMD completes recruitment
2
03/06/24 102 25K
03/06/24 Last post  Brett ebony Comments Created with Sketch.  102  Views Created with Sketch.  25K 
PER
Ann: Percheron to present at 2024 BIO International Convention 		31/05/24 23 5.5K
31/05/24 Last post  Brett ebony Comments Created with Sketch.  23  Views Created with Sketch.  5.5K 
PER
PER - Megathread
4 5 6
30/05/24 326 102K
30/05/24 Last post  itsagas Comments Created with Sketch.  326  Views Created with Sketch.  102K 

See All Discussions arrow Created with Sketch.

Timeline

Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
03 Jun 08:31
 
Percheron to present at 2024 BIO International Convention
31 May 08:32
 
Phase IIb study of ATL1102 in DMD completes recruitment
29 May 09:01
 
Preliminary Results of 9 Month Toxicology Study of ATL1102
27 May 09:41
 
US Patent Granted for ATL1102 in Duchenne muscular dystrophy
20 May 08:41
 
WHO selects proposed INN for ATL1102
06 May 08:52
 
View More arrow Created with Sketch.

Featured News

MEI Meteoric doubles REE resource at Caldeira in Brazil ahead of scoping study
right-arrow Created with Sketch.
SS1 Drill, drill, drill: 3 explorers with news on Friday – Sun Silver, Aurelia & PNX Metals
right-arrow Created with Sketch.
SIG Sigma Healthcare shares drop as ACCC waves red flag over Chemist Warehouse ASX listing
right-arrow Created with Sketch.
BGE Bridge SaaS shares soar as new CEO is announced
right-arrow Created with Sketch.
RAC Race delivers promising results in cancer drug mice research into heart complications
right-arrow Created with Sketch.
I88 Infini Resources logs two new uranium targets at Des Herbiers
right-arrow Created with Sketch.
(20min delay)
Last
9.2¢ 		Change
0.002(2.22%) 		Mkt cap ! $82.94M
Open High Low Value Volume
8.9¢ 9.2¢ 8.8¢ $69.71K 769.3K

Buyers (Bids)

No. Vol. Price($)
2 35742 9.0¢
 

Sellers (Offers)

Price($) Vol. No.
9.2¢ 84100 2
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
9.2¢ 		  Change
0.002 ( 3.37 %)
Open High Low Volume
8.9¢ 9.2¢ 8.8¢ 138646
Last updated 15.59pm 14/06/2024 ?
PER (ASX) Chart

Top Stories

Telix dips as pharma giant abandons US IPO for NASDAQ listing – despite record run

International plans for Telix – proudly boasting its intentions to list on the NASDAQ for a while now – have come to an anticlimactic end.
ASX Market Close: Consumer Discretionary rises ahead of interest rates decision | June 14, 2024 The ASX200 is down a third of a per cent to close the week. All sectors were in the red, except Consumer Discretionary stocks which pushed ahead, and, healthcare also made gains.
ASX Market Close: Unemployment dips as index climbs | 13 June, 2024 The Australian unemployment rate has dipped back down to 4%, defying expectations of a rise to 4.2%.Despite data suggesting the economy may not be cooling as quickly as the RBA is hoping, the market largely shrugged at the numbers, with the ASX200 closing up just over 0.5%.Most sectors recovered ...
Triangle gets approval for Perth Basin carbon sequestration project Triangle Energy has been given the green light for a carbon sequestration project to go ahead at its WA 31-L licence area in the Perth Basin.
Lightning spots additional pegmatites during first Brazilian visit Lightning Minerals Ltd has completed a successful first site visit to its newly acquired Brazilian lithium projects.

Featured News

SS1 Drill, drill, drill: 3 explorers with news on Friday – Sun Silver, Aurelia & PNX Metals
right-arrow Created with Sketch.
INF Infinity Lithium on the brink of full approval for San Jose project in Extremadura, Spain
right-arrow Created with Sketch.
MEI Meteoric doubles REE resource at Caldeira in Brazil ahead of scoping study
right-arrow Created with Sketch.
TSO Tesoro reports gold grading 173g/t in Chile, sending share price soaring
right-arrow Created with Sketch.
I88 Infini Resources logs two new uranium targets at Des Herbiers
right-arrow Created with Sketch.
BGE Bridge SaaS shares soar as new CEO is announced
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.